PHILADELPHIA, Oct. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced that Dr. Jonathan S. Berek, Professor and Chair, Obstetrics and Gynecology, Stanford University School of Medicine, presented new data on Ampligen(R) (Poly I : Poly C12U) at the Pacific Coast Oncology Gynecology Society Meeting, La Jolla, California, on October 1, 2009. The paper, entitled “Enhancing Dendritic Cell (DC) and Antibody Immunotherapy with Toll Receptor (TLR Agonists),” discusses the incorporation of a periodic “danger signal” into treatment regimens with a TLR3 agonist such as Poly I : Poly C12U and suggests such regimens may have broad potential application to boost the effects of immunotherapies of cancer.
